Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 4/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497500 | 0.97 | ALDH1A1 (0.33) | ALDH1A1CETPRPS6KB1TP53PTGER4 | |
| SCHEMBL4505878 | 0.88 | CETP (0.33) | CETPRPS6KB1PTGER4TOP2ATOP2B | |
| SCHEMBL4506276 | 0.84 | LMNA (0.34) | ALDH1A1CETPTP53PTGER4KDM4E | |
| SCHEMBL4504814 | 0.82 | CETP (0.36) | ALDH1A1CETPTP53TOP2ATOP2B | |
| SCHEMBL4718265 | 0.82 | CETP (0.40) | CETPRPS6KB1 | |
| SCHEMBL4500953 | 0.82 | CETP (0.40) | CETPRPS6KB1 | |
| SCHEMBL4718268 | 0.82 | CETP (0.40) | CETPRPS6KB1 | |
| SCHEMBL4516929 | 0.82 | CETP (0.40) | CETPRPS6KB1 | |
| SCHEMBL4500955 | 0.82 | CETP (0.40) | CETPRPS6KB1 | |
| SCHEMBL4493675 | 0.80 | CETP (0.46) | ALDH1A1CETPTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1999123-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107243-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107243-A1 | SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | ALDH1A1 1180/4885CETP 108/4885RPS6KB1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.